Riskpilot← Back to searchSign inGet full accessSemple Scientific AB
ABActiveOrg 5590748595Flyingeby 852Research and experimental development on natural sciences and engineering · NACE 7210Est. 20160 employees
Revenue 2025
SEK 501K
-68% vs 2024
EBITDA margin
8.9%
-89% vs 2024
Equity ratio
74.0%
Financial strength
Net profit 2025
SEK 32K
-90% vs 2024
| Revenue | SEK 501K | -68% |
| EBITDA | SEK 45K | -89% |
| Net profit | SEK 32K | -90% |
| Total assets | SEK 1,2M | -51% |
| Equity | SEK 880K | -39% |
| Employees | 0 | — |
Legal name
Semple Scientific AB
Org number
5590748595
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 september 2016
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Semple, Inger Agneta Elisabeth
Company purpose
Bolaget skall utföra konsultverksamhet inom grundforskning och utveckling av transfusionsmedicin, cellterapi och regenerative medicin inklusive läkemedel inom dessa områden samt därmed förenlig verksamhet.
Address
Flyingeby 852
Email
sempleelisabeth@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 54 | 87 | 1 279 | 1 565 | 501 |
| Staff expenses | — | — | — | −837 | −115 |
| EBITDA | 46 | 50 | 1 193 | 422 | 45 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 46 | 50 | 1 193 | 422 | 45 |
| Net financials | −1 | −1 | 2 | 4 | −1 |
| Profit before tax | 44 | 50 | 905 | 426 | 43 |
| Tax | −7 | −10 | −187 | −91 | −11 |
| Net profit | 37 | 40 | 719 | 335 | 32 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 918 | 958 | 2 132 | 2 408 | 1 190 |
| Equity | 904 | 944 | 1 513 | 1 448 | 880 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 14 | 14 | 329 | 670 | 20 |
| Total debt | 14 | 14 | 329 | 670 | 20 |
EBITDA margin
8.9%
This company
15.8%
Market median
-44% vs market
20212025
Equity ratio
74.0%
This company
38.2%
Market median
+94% vs market
20212025
Return on equity
3.7%
This company
18.4%
Market median
-80% vs market
20212025
Net profit margin
6.4%
This company
8.1%
Market median
-21% vs market
20212025
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20212025
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Semple Scientific AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| John Wesley Semple | Board of Directors | 0 companies |
| Inger Agneta Elisabeth Semple | Chairman | 0 companies |
| Emma Emelie Charlotta Ledent | Deputy Board Member | 0 companies |